ZOFRAN
LOE ApproachingNDAORALSOLUTION
Approved
Jan 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
ZOFRAN by Novartis. Approved for chemotherapy-induced nausea and vomiting, nausea, vomiting and 1 more indications. First approved in 1997.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOFRAN (ondansetron) is an oral solution antiemetic approved in 1997 for chemotherapy-induced nausea and vomiting, nausea, vomiting, and pruritus. It is a selective serotonin 5-HT3 receptor antagonist that blocks signals in the chemoreceptor trigger zone and vagal afferent pathways. This mechanism makes it a cornerstone therapy in oncology and post-operative settings.
LOE Approaching
With lifecycle status at LOE approaching, the ZOFRAN brand team is transitioning focus from market maintenance to line extension and lifecycle management strategies; expect smaller team sizes and strategic rather than growth-oriented roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (4)
Worked on ZOFRAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.